Senores Pharmaceuticals Share Price Today | Stock Price & Senores Pharmaceuticals Share Screener
As of November 18, 2026, the live Senores Pharmaceuticals share price (NSE: SENORES) is ₹1,092.60 on NSE and ₹1,092.15 on BSE, down 4.05% from the previous close, with shares trading between ₹1,083.00 and ₹1,145.70 in today's trading session, and a 52-week range of ₹710.25–₹1,550.90. Track SENORES market cap trends to gauge the company's total market size. Use the Senores Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Senores Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹201 and net income of ₹37, with EBITDA of ₹67, an operating margin of 30.0% and a profit margin of 18.4%.
Senores Pharmaceuticals Share Price Chart
Track the current stock price of Senores Pharmaceuticals with an interactive chart. Analyse SENORES share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Senores Pharmaceuticals stock quote in one place.
The quote of ₹1,092.60 sits between the 52-week low of ₹710.25 and the 52-week high of ₹1,550.90, and the latest session moved -4.05% from the previous close.
Senores Pharmaceuticals Company Profile - Fundamental Screener
Screen Senores Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SENORES shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE0RB801010.
Company Details
Classification
Identifiers and Leadership
Senores Pharmaceuticals Balance Sheet Screener
Screen SENORES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,604, up from ₹1,227 in 2025.
Latest statistics put total assets at ₹1,604 and shareholder funds at ₹934, with a leverage ratio of 0.38.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
Assets |
|||||
| Total Assets | 1,604 | 1,227 | 622 | 131 | 59 |
| Current Assets | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 726 | 301 | 235 | 27 | 7 |
Liabilities |
|||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 215 | 174 | 143 | 34 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||
| Total Equity | 934 | 812 | 232 | 46 | 37 |
| Share Capital | 46 | 46 | 31 | 10 | 9 |
| Reserves & Surplus | 888 | 740 | 174 | 36 | 28 |
Senores Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Senores Pharmaceuticals income statement and profit fundamentals. Analyze SENORES quarterly results. Senores Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹201 and net profit was ₹37, equal to earnings per unit of ₹8.85, at an operating margin of 30%.
In that period expenses were ₹135, interest cost ₹9 and tax ₹11. The next period listed, 2026-Jun, shows revenue of ₹183 and net profit of ₹31.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 201 | 183 | 193 | 178 | 159 | 134 | 126 | 108 | 100 | 80 | 104 | 80 |
| Expenses | 135 | 126 | 128 | 121 | 112 | 104 | 95 | 77 | 77 | 59 | 80 | 64 |
Operating Costs and Margins | ||||||||||||
| EBITDA | 67 | 57 | 65 | 58 | 47 | 30 | 31 | 31 | 23 | 21 | 24 | 16 |
| Operating Profit % | 30.00% | 30.00% | 27.00% | 29.00% | 27.00% | 20.00% | 17.00% | 25.00% | 21.00% | 26.00% | 22.00% | 19.00% |
| Depreciation | 10 | 10 | 9 | 8 | 8 | 6 | 5 | 4 | 4 | 4 | 4 | 3 |
| Interest | 9 | 7 | 9 | 5 | 6 | 5 | 5 | 6 | 5 | 5 | 3 | 3 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | 48 | 40 | 47 | 45 | 41 | 27 | 21 | 21 | 16 | 14 | 18 | 10 |
| Tax | 11 | 9 | 11 | 11 | 11 | 5 | 3 | 4 | 3 | 3 | 3 | 3 |
| Net Profit | 37 | 31 | 37 | 34 | 30 | 21 | 18 | 16 | 13 | 11 | 14 | 7 |
| EPS | 8.85 | 6.61 | 7.96 | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 | 3.39 | 8.03 | 4.01 |
Senores Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SENORES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹46, and net cash flow was an inflow of ₹98.
Over the same period, investing activities used ₹430 and financing activities provided ₹573.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
Cash from Operations and Investing | ||||
| Operating Activities | -46 | -26 | -1 | -10 |
| Investing Activities | -430 | -54 | -48 | -24 |
Financing and Net Cash | ||||
| Financing Activities | 573 | 87 | 46 | 37 |
| Net Cash Flow | 98 | 8 | -3 | 2 |
Senores Pharmaceuticals Shareholding Pattern Screener
See Senores Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Senores Pharmaceuticals promoter holding and ownership changes for SENORES on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 45.82%, foreign institutions 3.64%, domestic institutions 9.61% and the public 31.64%, spread across 34,126 shareholders.
The shareholder count was 34,126 in 2026-Mar, compared with 36,498 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Jul |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 45.82% | 45.82% | 45.82% | 45.77% | 45.78% | 45.80% | 45.80% | 66.66% |
Institutional Investors | ||||||||
| FII Holding | 3.64% | 6.62% | 6.01% | 4.17% | 3.67% | 4.28% | 3.35% | 0.00% |
| DII Holding | 9.61% | 9.77% | 10.84% | 9.65% | 9.51% | 8.61% | 9.31% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.64% | 29.25% | 29.39% | 31.43% | 31.44% | 31.09% | 31.94% | 0.00% |
| Other Holding | 9.30% | 8.55% | 7.94% | 8.97% | 9.60% | 10.22% | 9.59% | 33.34% |
| Shareholder Count | 34,126 | 36,498 | 42,642 | 37,653 | 36,389 | 34,917 | 34,401 | 177 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Senores Pharmaceuticals. Senores Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
Senores Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Senores Pharmaceuticals stock. Check SENORES index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 4 indices, including BSE INDEX BSE HC.
Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX BSEIPO, BSE INDEX SMLCAP, NIFTY IPO.
Complete Index List
Senores Pharmaceuticals Market Events Screener - Corporate Actions
Get Senores Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Senores Pharmaceuticals stock events that may affect SENORES share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 29, 2026, with a record date of October 29, 2026.
It is followed by Annual General Meeting dated September 25, 2026 and Quarterly Result Announcement dated July 27, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-29 | 2026-10-29 | Quarterly Result Announcement | NA | 8.26% |
| 2026-09-25 | 2026-09-25 | Annual General Meeting | NA | -7.30% |
| 2026-07-27 | 2026-07-27 | Quarterly Result Announcement | NA | 0.02% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 4.79% |
| 2026-01-31 | 2026-01-31 | Extraordinary General Meeting | NA | -6.84% |
| 2026-01-20 | 2026-01-20 | Quarterly Result Announcement | NA | -0.71% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.12% |
| 2025-09-18 | 2025-09-18 | Annual General Meeting | NA | -3.98% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -0.19% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 11.84% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -6.09% |
Senores Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen SENORES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Senores Pharmaceuticals Company Announcements - News & Reports Screener
Screen SENORES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated November 5, 2026 and October 30, 2026.
| Date | Update | Actions |
|---|---|---|
| Regulation 30 Disclosure Regarding Issuance Of Certificate Of GMP Compliance By The State Service Of Ukraine On Medicines And Drugs Control | - | |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-10-29 | Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants For The Quarter Ended On September 30 2026 | - |
| 2026-10-29 | Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On September 30 2026 | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-29 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-29 | Unaudited Financial Results For Quarter Ended September 30 2026 | - |
| 2026-10-29 | Board Meeting Outcome for Outcome Of Board Meeting Held On October 292026 | - |
| 2026-10-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-22 | Board Meeting Intimation for Approval Of The Un-Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-16 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-10-13 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-13 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,092.60, within a 52-week range of ₹710.25 to ₹1,550.90. The P/E ratio is 38.50 and the P/B ratio is 5.27, with earnings per unit of ₹26.39. Market capitalisation stands at ₹5,244.12 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 5 balance sheet periods, 12 income statement periods, 4 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.